Story Highlight
– Urgent action needed to protect pregnant women’s medication access.
– Pregnant women historically excluded from clinical trials.
– BPS calls for clear, evidence-based medication guidance.
– 80% of UK women take medication during pregnancy.
– Need for inclusive research and balanced healthcare training.
Full Story
Urgent measures are being called for to enhance the protection of pregnant women and new mothers, ensuring their safe access to essential medications. A prominent recommendation includes enabling their participation in clinical trials, a practice that has historically excluded this demographic.
The British Pharmacological Society (BPS) has noted that women often face crucial decisions regarding medication during pregnancy and while breastfeeding, yet they frequently lack comprehensive, evidence-based information to guide those choices. The advice available tends to concentrate disproportionately on the potential risks associated with medication, overshadowing its possible advantages.
In light of these concerns, a fresh position statement published by the BPS underscores the urgent need for clearer and evidence-based guidance on medication use throughout pregnancy and lactation. The statement reveals that approximately 80% of women in the UK rely on at least one medication during pregnancy or breastfeeding. Nevertheless, significant insufficiencies exist in safety and efficacy data due to the long-standing exclusion of these women from clinical trials.
This lack of robust information frequently leads to feelings of uncertainty and fear, resulting in inconsistent advice for patients dealing with chronic health conditions amidst pregnancy. According to the BPS, the information provided to pregnant women is often biased towards highlighting the dangers of medications rather than the potential benefits they may provide.
The BPS has outlined several key recommendations: it has advocated for more inclusive research that considers mothers-to-be and breastfeeding women, where safe and appropriate; the need for clear, balanced, and accessible information; and improved training for healthcare professionals.
Professor Cherry Wainwright, president of the British Pharmacological Society, remarked that “the BPS has released this statement because the current landscape leaves too many pregnant women navigating treatment without the clear, evidence-based guidance they deserve.” She highlighted that years of excluding pregnant women from clinical research have led to preventable gaps in safety data, culminating in uncertainty, postponed treatment, or unwarranted cessation of critical medications.
Professor Catriona Waitt, a National Institute for Health Research (NIHR) professor of clinical pharmacology and global health at the University of Liverpool, noted the shifting perspective on research involving pregnant women. She stated, “For quite a long time, people felt that maybe doing research in pregnancy was risky, but actually, the general perspective has changed over the years, that rather than protecting women from research, we should protect them through research.”
She further explained the consequences of the lack of data: “If we don’t know how a drug can safely and effectively be used in pregnancy and breastfeeding, sometimes a woman just doesn’t take the medication, so she runs the risk of untreated disease harm. Or sometimes she does take the medication but maybe if she’s breastfeeding, she decides not to breastfeed, and she’s deprived of the potential benefits to both her and her baby, simply because we don’t have the data.”
Additionally, she pointed out that women who adhere to prescribed medications may still experience significant anxiety regarding their treatment. “Most women require medication during pregnancy and breastfeeding, and for most drugs, we do not have the evidence base that women need to be able to make an informed decision about their health, and essentially, that is what we want to change.”
Dr Emma Magavern, a clinical lecturer in clinical pharmacology and an MRC clinician scientist at Queen Mary University of London, echoed these sentiments. She stressed that while most women take medication during pregnancy or breastfeeding, the evidence surrounding the safety and effectiveness of those medications is significantly more limited than what is typically expected for other populations. Pregnant and breastfeeding women have often been overlooked in clinical trials, the standard mechanism for determining the safety and efficacy of drugs.
Dr Magavern also highlighted the imbalance in communication regarding medication risks and benefits. “The communications around risk and benefit for the use of medication, with that underlying evidence base during pregnancy and breastfeeding, has skewed a bit in one direction,” she explained. “People are very aware of the risk to a foetus when taking medications during pregnancy or breastfeeding, and sometimes this is quite strongly emphasised at the expense of the other aspect, which is that there can be substantial risks to both the mother and baby if medical conditions are inadequately treated during pregnancy—a point that is often overlooked.”
The call for reform extends beyond just research practices. The BPS advocates for broader educational initiatives to improve the information available to both healthcare professionals and patients. The importance of ensuring that both mothers and healthcare providers have access to balanced, clear data cannot be overstated, as it directly impacts the healthcare decisions made by pregnant women and new mothers.
With the challenges posed by inadequate data, the healthcare community faces a pressing need to elevate awareness regarding the distinct needs of pregnant and breastfeeding women throughout the medication evaluation process. Experts argue that by embracing a more inclusive approach to clinical research, we can generate comprehensive data crucial for informed decision-making, ultimately safeguarding the health of mothers and their infants.
In conclusion, the current landscape of medication safety for pregnant and breastfeeding women necessitates immediate attention. Ensuring that these women are included in clinical trials and that they have access to balanced, evidence-based information is vital for both their health and that of their children. As the BPS emphasizes, transforming the approach to research and communication can significantly impact the wellbeing of families across the UK.
Our Thoughts
The article highlights significant gaps in the safety data for medications used by pregnant women and new mothers, primarily due to their historical exclusion from clinical trials. To prevent similar issues, it is crucial to ensure compliance with UK legislation, particularly the Medicines for Human Use (Clinical Trials) Regulations 2004, which could be enhanced to include provisions for the inclusion of pregnant and breastfeeding women in clinical research where safe and appropriate.
Key safety lessons include the need for balanced, evidence-based communication regarding the risks and benefits of medication during pregnancy. Healthcare professionals should receive better training on the complexities of treatment for this demographic, as outlined in the UK Health and Safety at Work Act 1974, which mandates that employers provide adequate information, instruction, and training.
Increasing participation of women in clinical trials and improving data collection on medication safety could significantly reduce the uncertainty and anxiety surrounding treatment options. Ensuring that communications around medication risks are proportionate and evidence-based would also align with the recommendations of the BPS, promoting better health outcomes for mothers and their babies.
